ODI PHARMA Aktie

 

Today, the 5[th] of December 2025, ODI Pharma AB (publ) held its Annual General Meeting ("AGM"). Below is a summary of the decisions made. All decisions were made with the required majority. Adoption of the income statement and balance sheet The AGM resolved to adopt the profit and loss account and balance sheet presented, and the consolidated income statement and consolidated balance sheet. Allocation of the company's profit or loss The AGM resolved to dispose of the company's results according to the adopted balance sheet, in accordance with the Board's proposal in the annual...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2025 - September 2025. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report. First quarter (2025-07-01 – 2025-09-30) · The Group's net sales amounted to SEK 5,968,143 (143,793). · The Group's profit after financial items amounted to SEK -37,027 (-1,468,183). · Result per share amounted to SEK -0.00 (-0.10).* · The solidity as of 2025-09-30 was 4% (9%).** * The Company's result per...

ODI Pharma AB (“ODI Pharma” or the “Company”) provides an operational update following recent improvements in its commercial performance. Strategic and practical measures implemented in recent quarters have begun to show clear results, supported by a more stable regulatory environment and smoother product flows into the Polish market. ODI Pharma's commercial activity has strengthened in recent months as earlier operational and strategic measures begin to take effect. The Company now benefits from a more stable supply situation, more predictable import and export processes, and an efficient...

The Board of Directors and the Chief Executive Officer of ODI Pharma AB (“ODI Pharma”) hereby publishes the annual report for the fiscal year 2024/2025. The annual report, along with the accompanying auditor's report, is available as an attached file and on the websites of ODI Pharma (www.odipharma.com) and Spotlight Stock Market (www.spotlightstockmarket.com). The auditor has made the following observation: Material uncertainty relating to going concern Without qualifying our opinion, we draw attention to the Directors' report on page 16 and note 18 of the annual accounts and...

The shareholders of ODI Pharma AB (publ), 559223–1392, are hereby invited to attend the Annual General Meeting on Friday, 5th of December 2025, at 15:00 at the company's premises at Östermalmstorg 1, 114 42 Stockholm Right to participate and registration Shareholders who wish to attend the Annual General Meeting shall · be included in the Euroclear Sweden AB share no later than the 27th of November 2025, and · sign up to the company no later than the 1st of December 2025, by e-mail to info@odipharma.com. The notification should state the full name, personal or corporate identity...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes the financial calendar for the 2025/2026 fiscal year. ODI's updated financial calendar is as follows: · Interim Report Q1 – November 27, 2025 · Annual General Meeting 2025 – December 5, 2025 · Half-year Report – February 26, 2026 · Interim Report Q3 – May 28, 2026 · Year-end Report 2025 – August 27, 2026 For more information on ODI Pharma, please contact: Volker Wiederrich, Chairman, ODI Pharma AB E-mail: info@odipharma.com   ODI Pharma AB ODI Pharma, based on its European network, subsidiaries and...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its year-end report for the period July 2024 - June 2025. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report. Fourth quarter (2025-04-01 – 2025-06-30) · The Group's net sales amounted to SEK 6,461 (7,544,320). · The Group's profit after financial items amounted to SEK -1,660,970 (-1,111,243). • · Result per share amounted to SEK -0.09 (-0.08). Twelve months (2024-07-01 – 2025-06-30) · • The Group's net sales amounted...

Today, 26 June 2025, an Extraordinary General Meeting was held in ODI Pharma AB (publ), reg. no. 559223-1392. Below is a summary of the decisions that were made. All decisions were made with the required majority. The notice to the general meeting and complete proposals are available on the Company's website, www.odipharma.com. The Board of Directors' proposals for a resolution on a directed issue of shares (item 7) The meeting approved of the resolution on a directed issue of shares to increase the company's share capital by SEK 70,769.24 through a new issue of 1,769,231 shares. The...

The Board of Directors of ODI Pharma AB (publ) (“ODI Pharma” or the “Company”) has resolved to propose a directed share issue of approximately SEK 2.0 million to strengthen the Company's financial position, enhance balance sheet flexibility and support the execution of ongoing operational activities. The proposal will be submitted for approval at an Extraordinary General Meeting scheduled to be held on 26 June 2025. Summary The Board of Directors of ODI Pharma has today resolved to propose that an Extraordinary General Meeting (EGM) approve a directed share issue of a total of 2,415,385...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2024 - March 2025. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report. Third quarter (2025-01-01 – 2025-03-31) · The Group's net sales amounted to SEK 2,934,337 (13,856,539). · The Group's profit after financial items amounted to SEK -340,612 (1,389,713). · Result per share amounted to SEK -0.02 (0.09).* Nine months (2024-07-01 – 2025-03-31) · The Group's net sales amounted to...

ODI Pharma AB (“ODI” or the “Company”) hereby publishes its half-year report for the period July 2024 – December 2024. The report is available as an attached document to this press release and on the Company's website (www.odipharma.com). Below is a summary of the report. Second quarter (2024-10-01 – 2024-12-31) · The Group's net sales amounted to SEK 0 (1,175). · The Group's profit after financial items amounted to SEK -2,562,520 (946,531). · Result per share amounted to SEK -0,16 (0.06).* Six months (2024-07-01 – 2024-12-31) · The Group's net sales amounted to SEK -4,965...

ODI Pharma AB ("ODI Pharma") hereby informs the termination of the agreement regarding the liquidity provider with Pareto Securities AB. The last day for the service of liquidity support by Pareto is March 14, 2025. The purpose of the liquidity provider has been to increase the liquidity of stock trading and reduce the volatility of the Company's stock to facilitate trading. The agreement with Parteo has now been terminated and will expire on March 14, 2025. For more information on ODI Pharma, please contact: Volker Wiederrich, Chairman, ODI Pharma AB E-mail: info@odipharma.com...

Today, the 30[th] of December 2024, ODI Pharma AB (publ) held its Annual General Meeting (“AGM”). A summary of the resolutions follows below. The resolutions were made with the required majority. For more detailed information on the content of the resolutions, please refer to the notice of the Annual General Meeting. Adoption of the income statement and balance sheet The AGM resolved to adopt the profit and loss account and balance sheet presented, and the consolidated income statement and consolidated balance sheet. Allocation of the company's profit or loss The AGM resolved to...

ODI Pharma AB's ("ODI" or the "Company") preferential issue of shares, with a subscription period ending on December 10, 2024, has now been registered at the Swedish Companies Registration Office. The Company hereby announces that the last day of trading in BTA (paid subscribed share) is December 27, 2024, and the stop day is January 2, 2025. In November 2024, ODI carried out a rights issue which provided the Company with approximately SEK 2.2 million before transaction costs. The rights issue has now been registered at the Swedish Companies Registration Office and the last day of trading in...

The subscription period in ODI Pharma AB's ("ODI" or the "Company") issue of shares with preferential right (the “Rights Issue”) ended on December 10, 2024. The Rights Issue was subscribed to a total of approximately 54.8 percent, including pre-subscription commitments. ODI will thus be provided proceeds of approximately SEK 2.2 million before deduction of transaction related costs. Subscription, allocation and payment The Rights Issue was subscribed to approximately SEK 2.2 million including pre-subscription commitments of approximately SEK 2.0 million, which corresponds to a...

ODI Pharma AB ("ODI" or the "Company") provides an update on Poland's expanding medical cannabis market, which remains an important focus of the Company's strategy. Recent regulatory changes in Poland highlight ODI's established position in one of Europe's most promising markets for medical cannabis. With ODI Pharma's sales during the current calendar year, ODI Pharma reached it's previously stipulated goal of achieving a substantial market share of more than 10%, resulting in a positive operational result for the shareholders of ODI for the financial year 2023/2024. ODI Pharma has...

Das Instrument 6OD SE0013409760 ODI PHARMA AB EQUITY wird ex Kapitalmassnahme gehandelt am 21.11.2024 The instrument 6OD SE0013409760 ODI PHARMA AB EQUITY is traded ex capital adjustment on 21.11.2024...

Das Instrument 6OD SE0013409760 ODI PHARMA AB EQUITY wird cum Kapitalmassnahme gehandelt am 20.11.2024 und ex Kapitalmassnahme am 21.11.2024 The instrument 6OD SE0013409760 ODI PHARMA AB EQUITY is traded cum capital adjustment on 20.11.2024 and ex capital adjustment on 21.11.2024...